Quality Assurance, Outcome Registration in Colorectal Cancer ...

This blog is a follow up to the original article first published in the EJCMO June 2011.

Prof Cornelis van de Velde

Despite the numerous national audit projects, international initiatives are limited. To generate the best care for colorectal cancer, and other solid tumours, in the whole Europe and to meet political and public demands for transparency, a deep and broad insight in treatment outcomes is needed union wide. A European audit registration, funded by EURECCA (European Registration of Cancer Care), will provide transparency, benchmarking, and feedback across nation?s borders. This can rapidly lead to treatment improvements and a decreased variation in the quality of care around the continent. It also provides opportunities to treat elderly and co morbid patients evidence based while it offers a unique insight in social-economical healthcare matters such as the consequences of commercialisation, treatment availability, and screening initiatives.

Momentarily, datasets are being harmonized to facilitate future analyses with the respect to national privacy legislations. The first analyses comparing the use of neo adjuvant treatment in rectal cancer have started. In 2012, a multidisciplinary consensus meeting will be organized in Perugia, Italy. The objective is to present extensive results at the 2013 ECCO-17 conference in Amsterdam, The Netherlands. As such, ECCO has established the basis for a strong, multidisciplinary audit structure with the commitment to improve cancer care for every European cancer patient. All information about EURECCA can be found on the webpage: www.canceraudit.eu

C.B.M. van den Broek, Research Fellow, Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.

V. Valentini, Professor of Radiotherapy, President Elect ESTRO, President Elect EURECCA, Universit? Cattolica S.Cuore, Rome, Italy.

C.J.H. van de Velde, Professor of Surgery, President Elect ECCO, President EURECCA, Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.

About the Authors

Cornelis J.H. van de Velde

Cornelis Jan Hadde van de Velde, born in The Netherlands received a PhD (cum laude) in breast cancer in 1977. He received his training at the Leiden University Medical Center in Leiden and at the M.D. Anderson Hospital in Houston in surgery and surgical oncology until 1982. In 1985 he was a visiting Professor at the Seoul National University Hospital in Korea and at the National Cancer Center Hospital in Tokyo, Japan. He was made a full clinical Professor of Surgery at the Leiden University Medical Center in 1988. In 1999 he was made a Honorary Fellow of the Royal College of Surgeons (London) and Royal College of Surgeons and Physicians (Glasgow). Prof. van de Velde?s primary areas of research include breast, colorectal, gastric cancer and endocrine tumors. He is a Coordinator of Oncology at the Leiden University Medical Center and is a member of a number of committees there. Prof. van de Velde is also Chairman of the Dutch Royal Academy of Sciences. He founded and was the first Chairman of the Dutch Colorectal Cancer Group, the Dutch Gastric Cancer Group and the Dutch Breast Cancer Group, past President of the European Society of Surgical Oncology and since 2010 President-Elect of ECCO, the European Cancer Organization.

Prof. van de Velde has supervised more than 60 Ph.D. theses, has been coordinator of 14 projects of the Netherlands Cancer Foundation (3 present), coordinator of 6 Health Insurance Fund Projects (Liver metastases, follow up, gastric cancer surgery, gastric cancer chemotherapy, rectal cancer surgery, radiotherapy and blood transfusion), coordinator of 6 European randomized breast cancer studies and coordinator of 4 European randomized colorectal cancer studies. Translational research on minimal residual disease and biomarkers that determine prognosis, genomic and proteomic profiling of tumors is the present focus of his research team.

Prof. van de Velde has presently authored more than 700 publications.

Source: http://www.ejcmo.tv/quality-assurance-by-outcome-registration-in-colorectal-cancer-eurecca-initiative/

charlie and the chocolate factory tampa bay buccaneers kansas city chiefs drag racer v3 drag racer v3 van van